News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
435,612 Results
Type
Article (27590)
Company Profile (133)
Press Release (407889)
Multimedia
Podcasts (81)
Webinars (11)
Section
Business (126859)
Career Advice (1188)
Deals (21937)
Drug Delivery (104)
Drug Development (60895)
Employer Resources (105)
FDA (9925)
Job Trends (9820)
News (224052)
Policy (21079)
Tag
Academia (1423)
Accelerated approval (3)
Adcomms (18)
Allergies (63)
Alliances (32597)
ALS (68)
Alzheimer's disease (818)
Antibody-drug conjugate (ADC) (115)
Approvals (9940)
Artificial intelligence (180)
Autoimmune disease (20)
Automation (9)
Bankruptcy (198)
Best Places to Work (7438)
BIOSECURE Act (18)
Biosimilars (101)
Biotechnology (60)
Bladder cancer (59)
Brain cancer (24)
Breast cancer (166)
Cancer (1551)
Cardiovascular disease (154)
Career advice (968)
Career pathing (22)
CAR-T (91)
Cell therapy (244)
Cervical cancer (12)
Clinical research (50555)
Collaboration (565)
Compensation (205)
Complete response letters (24)
COVID-19 (1506)
CRISPR (33)
C-suite (184)
Cystic fibrosis (68)
Data (1637)
Decentralized trials (2)
Denatured (20)
Depression (32)
Diabetes (195)
Diagnostics (3251)
Digital health (7)
Diversity (7)
Diversity, equity & inclusion (27)
Drug discovery (90)
Drug pricing (118)
Drug shortages (31)
Duchenne muscular dystrophy (67)
Earnings (47388)
Editorial (40)
Employer branding (13)
Employer resources (94)
Events (67151)
Executive appointments (546)
FDA (10766)
Friedreich's ataxia (3)
Frontotemporal dementia (4)
Funding (404)
Gene editing (71)
Generative AI (21)
Gene therapy (203)
GLP-1 (665)
Government (2562)
Grass and pollen (3)
Guidances (94)
Healthcare (10453)
Huntington's disease (14)
IgA nephropathy (27)
Immunology and inflammation (102)
Indications (23)
Infectious disease (1601)
Inflammatory bowel disease (105)
Inflation Reduction Act (8)
Influenza (29)
Intellectual property (61)
Interviews (147)
IPO (9154)
IRA (46)
Job creations (2671)
Job search strategy (882)
Kidney cancer (10)
Labor market (29)
Layoffs (314)
Leadership (16)
Legal (4836)
Liver cancer (42)
Lung cancer (232)
Lymphoma (108)
Machine learning (6)
Management (40)
Manufacturing (255)
MASH (64)
Medical device (4976)
Medtech (4980)
Mergers & acquisitions (13121)
Metabolic disorders (592)
Multiple sclerosis (54)
NASH (20)
Neurodegenerative disease (61)
Neuropsychiatric disorders (25)
Neuroscience (1199)
NextGen: Class of 2025 (3879)
Non-profit (2842)
Now hiring (23)
Obesity (346)
Opinion (206)
Ovarian cancer (50)
Pain (89)
Pancreatic cancer (57)
Parkinson's disease (101)
Partnered (13)
Patents (165)
Patient recruitment (67)
Peanut (29)
People (40520)
Pharmaceutical (76)
Pharmacy benefit managers (22)
Phase I (15598)
Phase II (21507)
Phase III (17182)
Pipeline (993)
Policy (151)
Postmarket research (2075)
Preclinical (6198)
Press Release (31)
Prostate cancer (88)
Psychedelics (17)
Radiopharmaceuticals (181)
Rare diseases (290)
Real estate (3744)
Recruiting (38)
Regulatory (15171)
Reports (26)
Research institute (1301)
Resumes & cover letters (192)
Rett syndrome (1)
RNA editing (3)
RSV (28)
Schizophrenia (65)
Series A (73)
Series B (40)
Service/supplier (7)
Sickle cell disease (47)
Special edition (16)
Spinal muscular atrophy (115)
Sponsored (14)
Startups (2264)
State (2)
Stomach cancer (10)
Supply chain (57)
Tariffs (51)
The Weekly (59)
Vaccines (402)
Venture capitalists (30)
Weight loss (254)
Women's health (18)
Worklife (11)
Date
Today (97)
Last 7 days (614)
Last 30 days (2060)
Last 365 days (20460)
2025 (7505)
2024 (22158)
2023 (24992)
2022 (34008)
2021 (35754)
2020 (33775)
2019 (28916)
2018 (22361)
2017 (21221)
2016 (20658)
2015 (23682)
2014 (18676)
2013 (15705)
2012 (17002)
2011 (17671)
2010 (16378)
Location
Africa (504)
Alabama (37)
Alaska (3)
Arizona (92)
Arkansas (10)
Asia (28773)
Australia (4023)
California (3513)
Canada (1421)
China (398)
Colorado (142)
Connecticut (133)
Delaware (123)
Europe (60775)
Florida (622)
Georgia (87)
Idaho (26)
Illinois (356)
India (22)
Indiana (222)
Iowa (6)
Japan (148)
Kansas (79)
Kentucky (20)
Louisiana (6)
Maine (14)
Maryland (528)
Massachusetts (2782)
Michigan (93)
Minnesota (208)
Mississippi (1)
Missouri (46)
Montana (22)
Nebraska (15)
Nevada (36)
New Hampshire (23)
New Jersey (1282)
New Mexico (21)
New York (1022)
North Carolina (655)
North Dakota (4)
Northern California (1509)
Ohio (107)
Oklahoma (7)
Oregon (23)
Pennsylvania (783)
Puerto Rico (12)
Rhode Island (21)
South America (866)
South Carolina (17)
South Dakota (1)
Southern California (1424)
Tennessee (53)
Texas (495)
United States (13845)
Utah (80)
Virginia (127)
Washington D.C. (53)
Washington State (302)
Wisconsin (37)
435,612 Results for "sumitomo pharma america".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sumitomo Pharma America Presents New Data on Vibegron at the 2025 American Urological Association Annual Meeting
April 30, 2025
·
7 min read
Press Releases
Sumitomo Pharma America enters into a Cooperative Research and Development Agreement with the National Cancer Institute to Advance Clinical Understanding of Enzomenib
April 14, 2025
·
5 min read
Press Releases
Foundation Medicine Collaborates with Sumitomo Pharma America to Advance Investigational Treatment for Patients with Acute Leukemia with NPM1 Mutations or KMT2A Rearrangements Using the FoundationOne®Heme Platform
February 19, 2025
·
4 min read
Press Releases
Sumitomo Pharma America Presents New Data on Nuvisertib and Enzomenib at the 2024 American Society of Hematology Annual Meeting
December 9, 2024
·
9 min read
Press Releases
Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
December 23, 2024
·
8 min read
Genetown
Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress
Sumitomo Pharma America, Inc. (SMPA) today announced the oral presentation of data from the ongoing Phase 1/2 first-in-human study of DSP-5336 in patients with relapsed or refractory acute leukemia at the European Hematology Association (EHA) 2024 Hybrid Congress.
June 14, 2024
·
7 min read
Drug Development
Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting
Sumitomo Pharma America, Inc., (SMPA) today announced the presentation of data from URO-901-3005, a Phase 3 randomized, double-blind, parallel-group, fixed-dose study evaluating the efficacy, safety, and tolerability of vibegron.
May 7, 2024
·
8 min read
Genetown
Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
Sumitomo Pharma America, Inc. (SMPA), announced today the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for vibegron.
May 13, 2024
·
7 min read
Press Releases
Mitsubishi Tanabe Pharma America to Present Research on ALS Pathology at the 2025 ALS Drug Development Summit
May 8, 2025
·
2 min read
Deals
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitomo Pharma Oncology, to Combine and Form Sumitomo Pharma America
Sumitomo Pharma Oncology, Inc., a wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sunovion Pharmaceuticals Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.
April 3, 2023
·
11 min read
1 of 43,562
Next
